Identification of cisplatin-binding sites on the large cytoplasmic loop of the Na+/K+-ATPase
Cisplatin is the most widely used chemotherapeutic drug for the treatment of various types of cancer; however, its administration brings also numerous side effects. It was demonstrated that cisplatin can inhibit the Na+/K+-ATPase (NKA), which can explain a large part of the adverse effects. In this...
Main Authors: | Jaroslava Šeflová, Petra Čechová, Tereza Štenclová, Marek Šebela, Martin Kubala |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2018.1445735 |
Similar Items
-
Flavonolignans as a Novel Class of Sodium Pump Inhibitors
by: Martin eKubala, et al.
Published: (2016-03-01) -
Na,K-ATPase isozymes in colorectal cancer and liver metastases
by: Marc eBaker Bechmann, et al.
Published: (2016-01-01) -
Cysteine residues 244 and 458–459 within the catalytic subunit of Na,K-ATPase control the enzyme's hydrolytic and signaling function under hypoxic conditions
by: Irina Yu. Petrushanko, et al.
Published: (2017-10-01) -
Effect of Reduction of Redox Modifications of Cys-Residues in the Na,K-ATPase α1-Subunit on Its Activity
by: Elena A. Dergousova, et al.
Published: (2017-02-01) -
Mechanisms of maintenance of cytoplasmic osmotic homeostasis in bryophytes cells under salinity stress
by: V. H. Kyyak, et al.
Published: (2019-12-01)